A Phase 1 interventional study of mRNA-1273 and mRNA-1010 in SARS-CoV-2, Seasonal Influenza and Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 8 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections — 2 open to participants now, 3 under way, none of them phase 3. 2019-nCoV Vaccine mRNA-1273 · Coronavirus Infections.
Among the 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections, this one is the 9th largest by enrollment, is the only one that started in 2022, is one of 2 in phase 1, and was the 8th registered.
1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.
Browse Coronavirus Infections studies →2 of the 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 3
First in 2020; this study’s year is marked. 1 started in 2022.
This study's enrollment of 308 is above the median of 120 across 655 interventional studies indexed under Coronavirus Infections.
Median enrollment 1,144 across the 11 interventional studies. Of the 8 that completed or were terminated, 6 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 11 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
30 studies in Coronavirus Infections by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 24 finished, 13 (54%) have results posted.
Among the 30 studies in Coronavirus Infections by Moderna, Inc., this one is the 16th largest by enrollment of the 21 interventional ones that give a count, is one of 8 that started in 2022, is one of 3 in phase 1, and was the 12th registered.
Moderna, Inc.’s Coronavirus Infections studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 11 studies testing 2019-nCoV Vaccine mRNA-1273 in Coronavirus Infections, from their registry updates:
Among Moderna, Inc.’s 30 in Coronavirus Infections:
This tab as a report to print or save as PDF → With an account.
The main goal of this study is to evaluate the safety, reactogenicity, and immunogenicity of study vaccines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single intramuscular (IM) injection of mRNA-1345 on Day 1.
Biological: mRNA-1345
Participants will receive single IM injection of mRNA-1647 on Days 1 and 57.
Biological: mRNA-1647
Participants will receive single IM injection of mRNA-1647 on Days 1, 57, and 169.
Biological: mRNA-1647
Participants will receive single IM injection of mRNA-1273 on Day 1
Biological: mRNA-1273
Participants will receive single IM injection of mRNA-1010 on Day 1.
Biological: mRNA-1010
Participants will receive single IM injection of FLUAD® on Day 1.
Biological: FLUAD®
Number of Participants With Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time frame: Up to Day 176 (7 days follow-up post-vaccination)
Number of Participants With Unsolicited Adverse Events (AEs)
Time frame: Up to Day 197 (28 days follow-up post-vaccination)
Number of Participants With Serious AEs (SAEs), AEs of Special Interest (AESIs), and AEs Leading to Study Withdrawal or Discontinuation of Study Vaccination
Time frame: Day 1 through end of study (EOS) (up to Day 1249)
Number of Participants with Medically Attended Adverse Events (MAAEs)
Time frame: Day 1 through Day 361
Geometric Mean Titer (GMT) of Serum Neutralizing Antibody Response for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, and mRNA-1345
Time frame: Days 1 (Baseline), 29, 85, and 197
Geometric Mean Fold-Rise (GMFR) of Serum Neutralizing Antibody Response for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, and mRNA-1345
Time frame: Days 1 (Baseline), 29, 85, and 197
Percentage of Participants With Seroresponse for mRNA-1010 (and Licensed Influenza Vaccine Comparator), mRNA-1273, mRNA-1345, and mRNA-1647
Time frame: Days 1 (Baseline), 29, 85, and 197
Ran from May 2022 to primary completion in Feb 2026, 45 months.
Of 35 industry-sponsored phase 1 interventional studies under Coronavirus Infections, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's 45 months is above that.
Counting every sponsor, half of 61 studies reached it within 10 months; a quarter within 3 and three quarters within 18.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · mRNA-1010 influenza vaccine · mRNA-1345 respiratory syncytial virus vaccine · mRNA-1647 cytomegalovirus vaccine